WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the results of an internal marketing study demonstrating that the Company’s predictive marketing technology, the Dynamic Audience Activation Platform (DAAP), can deliver superior program results for life sciences brands looking to reach and engage audiences that are complex to diagnose and treat.
As routine diligence, OptimizeRx monitors performance of all client programs with which we are engaged so we can study outcomes and better understand performance impact on our clients’ ability to measure return on marketing investment (ROI). In this instance, the study focused on a Major Depressive Disorder (MDD) therapy where a predictive targeting marketing campaign delivered nearly three times as many patients than the more traditional trigger-based marketing campaign.
The client executed two distinct programs in the marketing campaigns, using different targeting methodologies, on the OptimizeRx point-of-care network comprised of over 300 electronic health record (EHR), ePrescribing, telehealth, and practice management contributors. In the first program, the targeting methodology was trigger-based which is considered the current gold standard in point-of-care messaging. Messages were delivered based on specific clinical attributes, such as an ICD-10 code, found within the patient chart of a native electronic medical record (EMR). This program launched in late 2023 and ran for six months.
After the 6-month trigger-based program was completed, the brand elected to launch an additional engagement program leveraging DAAP for the same MDD therapy. AI-guided predictive marketing technology was added to the brand campaign to further enhance the timing of messaging and identify the appropriate audience composition for engaging HCPs with patients who could benefit most from the MDD therapy. After just 3-months of the new campaign, an early results comparison revealed significant advantages of a predictive marketing approach for this hard-to-reach audience compared to the traditional trigger-based model:
- Enhanced Audience Quality: DAAP identified nearly three times more brand-eligible patients per HCP per month compared to the trigger-based approach
- Increased script Lift: DAAP delivered 33% higher script lift per HCP per month
- Improvement in ROI: DAAP produced an increase in incremental revenue for the client, demonstrating a strong return on marketing investment
Data Overview
| Metric | Trigger-Based Approach (6 months results) | DAAP (3 months results) | Increase with DAAP |
| Avg. Brand-Eligible Patients per HCP/Month | 9 | 22 | 144% |
| Incremental Scripts per HCP/Month | 6 | 8 | 33% |
| Return-on-Investment | 4:1 | 7:1 | 75% |
“While trigger-based marketing can be effective for many therapies, our predictive marketing technology identified a meaningfully greater number of brand-eligible patients for our client,” commented Steve Silvestro, President of OptimizeRx. “This further substantiates the Company’s strategy to deliver more effective marketing campaigns for our clients via our patent-pending technology. We are seeing solid results with large brands looking to find more brand eligible patients as well as highly niche audiences that have been very costly for pharma to engage in the past.”
“While the results of the initial trigger-based marketing campaign were considered a success by the client, and we’ve seen similar results on these types of campaigns going back to 2016,” continued Silvestro, “DAAP showed an impactful improvement in targeting effectiveness and efficiency that raised the bar on return expectations, challenging the status quo of pharma marketing.”
The results of this DAAP campaign represent significant growth potential in script impact and overall campaign scale, driving higher effectiveness than the original trigger-based approach. Given the positive results observed in this study, the outreach program powered by DAAP is ongoing.
About OptimizeRx
OptimizeRx provides trailblazing technology that fosters care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the healthcare journey. With the ability to synchronize messaging across 2 million healthcare providers and over 240 million adults across a multitude of digital channels including a proprietary point-of-care network, OptimizeRx is changing the way life sciences engages with customers.
For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
OptimizeRx Contact:
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
